Weill Cornell Medicine shared on LinkedIn:
“Weill Cornell Medicine has received a $2.5 million, three-year grant to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.
The highly competitive U.S. Department of Defense Breast Cancer Research Program Breakthrough Award supports innovative projects with strong potential to transform breast cancer treatment.
Weill Cornell Medicine’s Dr. Xiaojing Ma is working with Dr. Gang Lin to develop first-in-class drugs targeting the protein UBR5, which is frequently overproduced in aggressive breast cancers and several other difficult-to-treat malignancies.”
‘This award provides an opportunity to translate years of basic discovery into therapies that could ultimately benefit patients.’ – Xiaojing Ma
‘A big win will be optimizing these drug candidates and generating the data needed to move into the next phase of development.’ – Gang Lin
Proceed to the video attached to the post.
Other posts about Weill Cornell Medicine on OncoDaily.